Expression of CD44 molecules and CD44 ligands during human thymic fetal development: expression of CD44 isoforms is developmentally regulated by Patel, Dhavalkumar D. et al.
International Immunology, Vb/. 7, No. 2, pp. 277-286 © 1995 Oxford University Press
Expression of CD44 molecules and CD44
ligands during human thymic fetal
development: expression of CD44 isoforms
is developmentally regulated
Dhavalkumar D. Patel, Laura P. Hale1, Leona P. Whichard, Gilbert Radcliff,
Charles R. Mackay2 and Barton F. Haynes
Department of Medicine, Division of Rheumatology, Allergy and Clinical Immunology, Department of
Immunology, and Duke University Arthritis Center, Duke University Medical Center, Durham, NC 27710,
USA
department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
2Basel Institute for Immunology, Basel, Switzerland
Key words: CD44, differentiation, fibronectin, hyaluronan, thymus
Abstract
It has recently been recognized that CD44 comprises a large family of alternatively spliced forms.
In the thymus, CD44 has been postulated to play an important role In immature T cell migration
and maturation. In this paper, we have studied the expression of CD44 molecules and two CD44
ligands, hyaluronan (HA) and fibronectin (FN), during human thymic fetal development. We found
that mAbs against all CD44 Isoforms (A3D8 or A1G3) reacted with both thymic epithelial (TE) cells
and thymocytes beginning at the time of initial colonization of the human thymus by hematopoietic
stem cells at 8.2 weeks of fetal gestation. However, mAbs specific for splice variants of CD44
containing membrane-proximal inserts (11.24, 11.10 and 11.9) reacted only with terminally
differentiated TE cells in and around Hassall's bodies beginning at 16-19 weeks of fetal gestation.
Studies of differentiated versus undlfferentlated TE cells In vitro confirmed the selective expression
of CD44 variant isoforms on terminally differentiated TE cells. Expression of HA and FN was
determined by fluorescence microscopy using either blotlnylated-HA binding protein or an antl-FN
mAb. We found that whereas FN was present throughout the human fetal thymus beginning at 8.2
weeks, HA was not present until 16 weeks of gestational age. These data demonstrate the
differential expression of standard versus variant CD44 isoforms during thymic ontogeny and
Implicate CD44 interactions with ligands other than HA as important in the earlier stages of human
thymus development.
Introduction
The CD44 family of glycoproteins is comprised of multiple
alternatively-spliced isoforms that are expressed on a wide
variety of cell types including hematopoietic and epithelial
cells (reviewed in 1,2). Hematopoietic cells predominantly
express the most common, or standard, 85-95 kDa form of
CD44 (CD44S) encoded by exons 1-5, 15-17 and 19 (Fig. 1).
In addition to CD44S, epithelial and some hematopoietic cells
may also express variant isoforms of CD44 (CD44v) via
alternative splicing of at least nine exons (v2-v10) in humans
(3) and 10 exons (v1-v10) in rodents (2).
CD44 molecules have been postulated to be involved in
a variety of processes including lymphocyte homing, cell
migration, cell-cell and cell-substrate interactions, lympho-
poiesis, and T cell activation (reviewed in 4-6). In both
humans and rodents, expression of variant isoforms of CD44
containing v6 has been associated with a metastatic pheno-
type of epithelial cell malignancies (7-12).
In the thymus, CD44 expression has been implicated in
mediating homing of T cell precursors to the thymus (reviewed
in 4,6) and CD44 molecules are more highly expressed on
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Fig. 1. CD44 genomic structure and reactivity of antibodies to CD44. A schematic representation of the genomic structure of the human
COM gene, as described by Screaton et al. (3), is shown at the top. The extracellular portion of standard forms of CD44 is depicted by open
rectangles, the intracellular portion by cross-hatched rectangles and the exon encoding the transmembrane (TM) region is depicted by a
filled rectangle. The human CD44 gene exons (exons 6-14 or v2-v10) that can be alternatively spliced into the mRNA to form higher molecular
weight variant isoforms of CD44 are depicted by stippled rectangles. Rodent CD44 genes contain an additional variant exon (v1), indicated
by a stippled rectangle with a question mark, between human CD44 exons 5 and 6 (2). A depiction of mRNA encoding the most common
form of CD44 is shown. Standard forms of CD44 may have short (exon 18) or long (exon 19) cytoplasmic domains Reactivities of the CD44
antibodies used in this study are shown at the bottom. mAbs A3D8, A1G3 and 5F12 react with conformational epitopes in the extracellular
portion of standard CD44 (19). Antibodies 11.10, 11.31 and 11.24 react with portions of CD44 encoded by exons v4, v6 and v9 respectively (16).
medullary versus cortical thymocytes (13,14). Variant isoforms
of CD44 are transiently expressed on stimulated peripheral
blood B cells, T cells and constitutively expressed on mono-
cytes/macrophages (15,16).
Mackay et al. have demonstrated expression of CD44 vari-
ant isoforms containing v4, v6 and v9 inserts in Hassall's
bodies (HB) in post-natal thymus (16). In this study, we have
examined the expression of CD44 isoforms and two CD44
ligands, hyaluronan (HA) and fibronectin (FN), throughout
human fetal thymic development.
Methods
Antibodies
The following mAbs were used: A3D8, A1G3 and 5F12 (all
isoforms of CD44) (17-19); 11.10 (CD44 isoforms containing
exon v4) (16); 11.31 (CD44 isoforms containing exon v6) (16);
11.24 (CD44 isoforms containing exon v9) (16); AE-1, AE-2
and AE-3 (anti-keratins, from T. T. Sun, NYU, New York) (20);
TE4 [medullary thymic epithelial (TE) cells] (21); TE7 (thymic
stroma and fibroblasts) (21); TE19 (HB) (22); STE1 (HB)
(D D. Patel etal., unpublished); LeuM3 (monocytes) (23);
3A1e (pan T cell marker CD7) (24); 1B10 (fibroblasts) (25);
FN15 (FN) (Sigma, St Louis, MO); and P3 x 63/Ag8(P3) (lgG1
control mAb) (ATCC, Rockville, MD). mAb 11.24 has been
shown to be specific for exon v9 containing isoforms of CD44
by peptide binding studies (16). To confirm that mAb 11.24
did not cross-react with other cell surface proteins and was
specific for CD44v9, we tested the ability of mAb 11.24 to
react with Jurkat cells that did not express any form of CD44
(Jurkat parent), Jurkat cells that expressed the standard form
of CD44 with no variant exons (Jurkat/CD44S) and Jurkat
cells that expressed a form of CD44 containing exons v8-
v10 (Jurkat/CD44v8-10) (19). mAb 11.24 reacted only with
Jurkat cells that expressed the isoform of CD44 containing
exons v8-v10, further demonstrating the specificity of mAb
11.24 for exon v9 of CD44 (not shown).
Indirect immunofluorescence of human thymic tissues
Post-natal thymic tissues, taken as a necessary part of
surgical procedures, were obtained from children undergoing
corrective cardiovascular surgery as discarded tissue from
the Department of Pathology, Duke University Medical Center.
Fetal tissues were obtained as discarded tissue from the
Department of Pathology, Duke University Medical Center,
from either elective first trimester abortions or at the time of
surgery for ectopic pregnancy. Gestational age was deter-
mined by crown-rump length, menstrual records and fetal
part morphology. Frozen tissue specimens were embedded
in OCT compound, cut into 4 nm sections and fixed in
acetone for 5 min at -70°C. mAbs were used in indirect
immunofluorescence assays with fluorescein-conjugated goat
anti-mouse IgG (GAM-FITC) (Kirkegaard & Perry, Gaithers-
burg, MD) as described (26). Biotinylated HA binding protein
(HABP) (Pel-Freez, Rogers, AK) (27) was also used in indirect
immunofluorescence assays with fluorescein-conjugated
streptavidin (Southern Biotechnology Associates,
Birmingham, AL). The specificity of HABP binding to tissues
was determined by inhibition of HABP-biotin binding to thymus
tissues with HA (Sigma). We found that binding of 0.1 \LQ of
HABP-biotin to fetal skin and to fetal and post-natal thymus
was completely inhibited by 12.5 u.g of unlabeled HA (not
shown)
Cell culture conditions
TE cells were cultured by an explant technique and propag-
ated in enriched medium (containing epidermal growth factor
and insulin) on mitomycin C-treated 3T3 fibroblast feeder
layers as previously described (28). Thymic fibroblasts were
removed by treatment with 0.02% EDTA in PBS followed by
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Table 1. Expression of CD44 molecules in human fetal and postnatal thymus
Fetal
Postnatal
Thymus no.
58
48
22
40
56
57
59
21
26
18
25
320
422
444
159
Gestational age
8 2 weeks
9 2 weeks
10 weeks
12 75 weeks
13 weeks
16 weeks
17 weeks
19 weeks
25 weeks
26 weeks
34 weeks
6 days
7 days
3 months
26 months
Reactivity with
A3D8
(all CD44)
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
C+,M*+
C+ ,M2 +
C+ ,M2 +
C+ ,M2 +
mAb
A1G3
(all CD44)
C+ / " ,M 2 +
C+'-.M2*
C+'-.M2*
C + / - ,M 2 +
C + / - ,M 2 +
C + / - ,M 2 +
C + / - ,M 2 +
C + / - ,M 2 +
C + / - ,M 2 +
C + / - ,M 2 +
C+ / " ,M 2 +
C+ / " ,M 2 +
C+ / " ,M2 +
C+'-.M2*
11 24
(CD44v9)
rare cells
faint +, most -
ND
ND
ND
rare + cells
in medulla
_
HB+, scattered
medullary TE cells
HB+
HB+, scattered
medullary TE cells
HB+
HB+
HB+
HB+
HB+
11.10
(CD44v4)
ND
ND
ND
_
_
-
_
rare + cells in
medulla
—
HB+
HB+
HB+
HB+
HB+
HB+
11.31
(CD44v6)
ND
ND
ND
_
_
-
_
-
_
HB+
HB+
HB+
HB+
HB+
HB+
HB = Hassall's bodies; C = cortex; M = medulla; + = all cells positive; 2+ = a degree of brightness greater than +, + / - = a subset
bright positive; - = all cells negative; ND = not done.
complement-mediated lysis with anti-fibroblast mAb 1B10
(25). 3T3 fibroblast feeder layers were removed by treatment
with 0.02% EDTA in PBS prior to detachment of TE cells from
culture dishes with 0.05% trypsin in PBS containing 0.02%
EDTA. TE cell preparations were >95% positive for the keratin
markers AE-1 and AE-3, 0-5% positive for the fibroblast
marker TE7, and negative for the macrophage marker LeuM3
and thymocyte marker CD7. Cultured TE cells were allowed
to spontaneously differentiate in vitro over time (3-12 weeks)
to squamous forms with a large flattened cellular morphology
(29) or were induced to differentiate with the addition of
varying amounts of retinoic acid (Sigma) to DME (Gibco,
Grand Island, NY) containing 5% FCS without growth factors.
Terminally differentiated TE cells had a characteristic squam-
ous cell morphology, and were positive for markers of differen-
tiated TE cells including TE19 (22), STE1 and STE2 (D. D.
Patel etal., unpublished data).
Thymocytes were obtained by separation from thymus
tissue and purified by density gradient centrifugation as
described (30). Thymocytes were used immediately or frozen
in media containing 20% FCS, 7.5% dimethylsulfoxide and
10 ng/ml gentamicin (BioWhittaker, Walkersville, MD) in RPMI
1640 until use (30). Thymocytes were cultured in growth media
containing 15% human A serum and 10|ig/ml gentamicin in
RPMI 1640 at a density of 2 x 106 cells/ml. Thymocytes were
activated with 5 U/ml rlL-2 (Cetus, Emeryville, CA) and either
2 u,g/ml phytohemagglutinin (PHA; Sigma) or 100 (ig/ml con-
canavalin A (Con A; Sigma) in growth media for 96 h and
washed with 0.3 M methyl a-o-mannopyranoside (aMM;
Sigma) prior to analysis (18).
Peripheral blood mononuclear cells (PBMC) were purified
(30) and cultured in media containing 15% human A serum
and 10 u,g/ml gentamicin in RPMI 1640. PBMC were activated
with 0.5 ng/ml PHA or 10 u.g/ml Con A (18) and washed with
0.3 M aMM in RPMI 1640 prior to analysis
Detection of cell surface antigens
Unfixed cultured cells were suspended in PBS containing 2%
BSA and 0.1 % NaN3, stained by indirect immunofluorescence,
and analyzed on a FACStar Plus (Becton Dickinson, Mountain
View, CA). Data was further processed using the software
program PC Lysys (Becton Dickinson).
Detection of antigens immobilized on nitrocellulose
Cells were harvested as described above and lysed, or lysed
in situ without trypsin treatment, in a buffer containing PBS,
2% NP-40, 1 mM phenylmethylsulfonyl fluoride and 0.1 mM
tosyl-L-lysyl chloromethylketone. A soluble protein extract
was prepared by centrifugation (10,000 g) for 30 min at 4°C.
Proteins were separated by polyacrylamide gel electrophor-
esis and electrophoretically transferred to nitrocellulose filters.
Antigens on nitrocellulose filters were detected by indirect
immunoperoxidase staining using horseradish peroxidase-
conjugated goat anti-mouse IgG antibodies (Promega, Madi-
son, Wl). Protein bands were visualized by incubation with
Rennaisance™ chemiluminescence reagent (DuPont NEN,
Boston, MA) followed by exposure to autoradiography film.
Results
CD44 expression in human fetal thymus throughout thymic
ontogeny
The expression of CD44 isoforms in human thymus was
initially determined by testing frozen sections of human thymus
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Fig. 2. Ontogeny of expression of CD44 molecules in human fetal thymus. Panels (aHc) show fetal thymus no. 58 from 8.2 weeks of gestation
just at the time of colonization of the thymus rudiment by hematopoietic stem cells. Panel (a) shows reactivity of mAb A1G3, panel (b) shows
reactivity of mAb A3D8 and panel (c) shows reactivity of mAb 11.24. Panels (a) and (b) show that A1G3 and A3D8 react more strongly with
central portions of the thymus (below the dotted lines) and weakly with the outer portions of the thymic rudiment above the dotted lines. The
large dark areas separating portions of the thymus are artifact from snap-freezing the tissue. In panel (c), the thymus areas (t) of the right
thymus of tissue no. 58 are negative for 11.24. There were only scattered 11.24+ cells in an interlobular septae in the left thymus of tissue no.
58. Panels (dH' ) show sequential sections from the same area of fetal thymus no. 56 from 13 weeks of fetal gestation. Medullary areas are
below the dotted lines and cortical areas above the dotted lines. Panel (d) shows reactivity with antibody A1G3, panel (e) shows reactivity
with mAb A3D8 and panel (f) shows reactivity with mAb 11.24. Whereas A1G3 and A3D8 reacted well with fetal thymus no. 56, 11 24 did not
react. The arrows in panel (f) show autofluorescent areas. mAb 11.24 reacted strongly with HB and TE cells around HB beginning at -19
weeks of gestation. Panel (g) shows reactivity of mAb 11.24 with fetal thymus no. 18 from 26 weeks of gestation, while panels (h) and (i) show
reactivity of fetal thymus no. 25 from 34 weeks of gestation with antibody A3D8 in panel (h) and 11 24 in panel (i). Cells around early HB are
shown in panel (g) between the arrowheads, while H points out HB in panels (h) and (i). An arrowhead also shows a smaller HB in panel (i).
All panels were photographed at a magnification of X400.
for reactivity with mAbs to all forms of CD44 (A3D8, A1G3),
and mAbs 11.24, 11.10, 11.31 to isoforms containing CD44v9,
CD44v6 and CD44v4 respectively (16). Fetal thymus tissues
ranging from the time of initial colonization of fetal thymus by
hematopoietic stem cell precursors (8.2 weeks of gestation)
to 34 weeks of gestational age were tested (Table 1). Whereas
mAbs A3D8 and A1G3, that react with two distinct epitopes
on all CD44 isoforms, reacted with TE cells, fibroblasts and
thymocytes of all fetal thymuses tested, mAb 11.24 did not
react with TE cells or thymocytes in 8.2 (no. 58), 13 (no. 56)
or 17 (no. 59) week thymus (Fig. 2). Rare 11.24 reactive
medullary TE cells were present in thymus no. 57 (16 weeks
gestational age). Thymuses 19 weeks of gestational age and
older contained swirls of terminally differentiated TE cells (HB)
and mAb 11.24 reacted with fetal thymuses &19 weeks of
age in a HB-specific pattern (Fig. 2). mAbs against other
CD44 variant isoforms containing v4 (11.10) and v6 (11.31)
inserts reacted with rare HB in fetal thymus no. 21 (19 week),
did not react with thymus no. 26 (25 week) HB, and reacted
with fetal thymus 18 (26 week) and 25 (34 week) as well as
with post-natal thymus in a HB-specific manner. Thus, these
data suggested that expression of CD44 variant isoforms
containing exon 13 (variant exon 9), exon 10 (variant exon 6)
and exon 8 (variant exon 4) are hallmarks of terminally
differentiated TE cells. As previously reported (21), in post-
natal human thymus, anti-CD44 mAbs A3D8 and A1G3
reacted brightly with TE cells, and with medullary and cortical
thymocytes (not shown). In addition, mAbs A3D8 and A1G3
also reacted with thymic macrophages containing lipofuscin
pigment, with thymic vessels, and with thymic fibroblasts in
interlobular septae and the thymic capsule. In contrast, in
post-natal thymus the pattern of reactivities of mAbs 11 24,
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Thymocytes
PBMC
Fig. 3. Expression of CD44 isoforms on human thymocytes and
PBMC Freshly isolated thymocytes (A), PHA/IL-2 activated
thymocytes (B), PBMC (C) and PHA/IL-2 activated PBMC (D) were
incubated with mAb 5F12 or 11.24. Cells were analyzed by indirect
immunofluorescence and flow cytometry and their histograms are
shown. The profile of control IgG P3x63/Ag8 preparation (P3) is also
shown in each panel. Data are representative of three experiments
Fig. 5. variant isoforms of CD44 containing exon v9 are expressed
selectively on terminally differentiated TE cells. TE cells from primary
cultures that contained morphologically and phenotypically terminally
differentiated cells were assayed by indirect immunofluorescence for
reactivity with A3D8 (A) and 11.24 (B) The smaller proliferating TE
cells (indicated by filled arrows) were high expressers of CD44 but
were negative for isoforms containing exon v9. The larger terminally
differentiated TE cells (indicated by open arrows) were low expressers
of total CD44 and positive for isoforms containing exon v9 Data are
representative of six experiments. (X400.)
Undifferentiated Differentiated
Fig. 4. Photomicrographs of TE cells at different stages of
differentiation. Shown are photomicrographs of TE cells that were
rapidly proliferating (A) and TE cells that were terminally differentiated
(B). Note that the proliferating, undifferentiated TE cells are small
and that the terminally differentiated TE cells are large Data are
representative of three experiments. (X100 )
11.31 and 11.10 was identical to their reactivity with 34 week
fetal thymus (no. 25), with reactivities to HB, TE cells around
HB and with pigment-containing cells that likely were macro-
phages.
Expression of CD44v9, v4 and v6 on activated thymocytes
and PBMC
In indirect immunofluorescence assays and flow cytometry
analysis, neither unstimulated thymocytes nor PBMC reacted
with mAb 11.24 (Fig. 3A and C). To determine if CD44v9
expression in thymus was limited to TE cells, we tested the
ability of PHA and Con A to induce CD44v9 expression in
thymocytes and PBMC. PHA has been shown to induce
CD44v6 and CD44v9 expression in human PBMC (16), and
to induce CD44v6 in rat T cells (15). PBMC, when activated
A3D8
11.24
Fig. 6. Cell surface reactivity of CD44 mAbs to cultured TE cells.
The pattern of reactivity of mAbs to all forms of CD44 (A3D8) and
variant isoforms containing exon v9 (11.24) on cultured TE cells that
displayed a morphology of proliferating (A and C) or terminally
differentiated (B and D) cells is shown. TE cells with a morphology
of actively proliferating cells expressed high levels of CD44 but did
not express variant isoforms containing exon v9. TE cell cultures with
a predominantly terminally differentiated cell morphology had two
subsets of cells based on the expression of CD44 isoforms. Based
upon analysis of forward scatter versus fluorescence, the larger
differentiated cells expressed low levels of total CD44 and low levels
of CD44v9; the smaller undifferentiated cells expressed high levels of
total CD44 and no CD44v9. Data are representative of 12 experiments.
with either PHA or Con A, could be induced to express
CD44v9 (Fig. 3D) but not v4 or v6 (data not shown), as
detected by indirect immunofluorescence with mAbs 11.24,
11.10 and 11.31 respectively, and flow cytometry. Neither
unstimulated thymocytes nor thymocytes activated with either
PHA/IL-2 or Con A/IL-2 for 4 days expressed detectable levels
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time (days) of RA treatment
Fig. 7. RA induces differentiation of TE cells and up-regulation of variant isoforms of CD44. The morphology of control TE cells and TE cells
treated for 96 h with 10"6 M RA are shown in panels (A) and (B) respectively (x 100). The RA-treated cells were larger and were morphologically
similar to terminally differentiated TE cells. RA-treated cells were also phenotypically more differentiated than control as they reacted with
TE19 mAb. Panel (C) shows a representative of a time course of RA treatment of TE cells. TE cells were cultured in enriched media containing
10"6 M RA for 0-7 days and their differentiation status was determined by phenotypic analysis Shown is the percentage of 11 24+ and TE19+
cells in TE cell cultures stimulated for 0-7 days with RA. Data are representative of three experiments.
of CD44v9 (Fig. 3B), v4 or v6 (data not shown) on their
surface. In a separate experiment using thymocytes from three
different individuals, only 2±2% of thymocytes stimulated for
4 days with PHA/IL-2 and 5 ± 1 % of thymocytes stimulated for
7 days with PHA/IL-2 expressed detectable levels of CD44v9;
no CD44v4 or v6 expression was detected on thymocytes at
either 4 or 7 days of stimulation with PHA/IL-2. Thus, CD44v9,
v4 and v6 reactivity in thymus was limited primarily to TE cells
and in the case of CD44v9, also to scattered pigment-
containing macrophages.
Expression of CD44 isoforms on cultured TE cells
To confirm the notion that terminally differentiated TE cells
expressed CD44 variant isoforms, further studies were per-
formed on cultured TE cells using the CD44v9 mAb, 11.24.
TE cells spontaneously differentiate in vitro in culture from
small proliferating cells (Fig. 4A) to larger non-proliferating
terminally differentiated cells (24,29) (Fig. 4B). Large TE cells
were found to be phenotypically differentiated as they were
reactive with mAbs TE19 (31) and STE1 (D. D. Patel and
B. F. Haynes, unpublished), markers of terminally differenti-
ated TE cells. In TE cell cultures containing spontaneously
differentiated TE cells, cells with a morphology of small
undifferentiated cells reacted with anti-CD44 mAb A3D8
brightly (Fig. 5A) but did not react with mAb 11.24 (Fig. 5B).
TE cells with a large terminally differentiated (squamous)
morphology reacted with mAb A3D8 dimly (Fig. 5A) and were
strongly reactive with mAb 11.24 (Fig. 5B).
These data also suggested that expression of total CD44
in the large differentiated TE cells was lower than that in the
small proliferating TE cells. To test this hypothesis, TE cells
from cultures that were either undifferentiated or well differenti-
ated were further analyzed by indirect immunofluorescence
assays and flow cytometry comparing reactivity with mAbs
A3D8 and 11.24 (Fig. 6). TE cells from undifferentiated TE
cultures expressed high levels (~2 logs mean fluorescence
channel above background) of total surface CD44 as deter-
mined by reactivity with mAb A3D8 (Fig. 6A) and did not
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Fig. 8. Detection of CD44 proteins immobilized on nitrocellulose
filters. Protein extracts from thymocytes and TE cells at different stages
of differentiation were separated by discontinuous polyacrylamide gel
electrophoresis, transferred to nitrocellulose and reacted with mAb
A3D8 or control mAb (P3) mAbs were visualized by indirect
immunoperoxidase and chemilummescence. Panel (A) shows the
reactivity of control mAb p3 with (1) thymocytes and (2) thymic
epithelial cells. Panel (B) shows the reactivity of mAb A3D8 with
(1) thymocytes and (2) TE cells from a culture containing 90%
undifferentiated TE cells. Panel (C) represents an overexposure of
panel (B) to show the high molecular weight isoforms of CD44 which
are present in low abundance. Panel (D) shows the reactivity of mAb
A3D8 with (1) thymocytes and (2) TE cells from a culture containing
>95% terminally differentiated TE cells. Data are representative of
three experiments.
express surface CD44v9 detectable by mAb 11.24 (Fig. 6C).
TE cells from differentiated TE cultures contained two popula-
tions of cells based on expression of total CD44 (Fig. 6B) and
CD44v9 (Fig. 6D), one that expressed high levels of CD44
and no CD44v9, and the other that expressed lower levels of
CD44 and low levels of CD44v9. As determined by analysis of
fluorescence versus forward scatter, the small cells expressed
high levels of surface CD44 but did not react with mAb 11.24,
and the large cells expressed low levels of both surface CD44
and CD44v9 (not shown). Thus, these data confirm that while
total CD44 expression decreased with terminal differentiation
of TE cells, expression of CD44v9 increased.
Retinoic acid-induced differentiation of TE cells
To further test the hypothesis that CD44v9 expression on TE
cells was limited to differentiated cells, we treated TE cells
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Fig. 9. Ontogeny of CD44 ligands FN and HA during human fetal thymic development. Panels (a)-(c) show reactivity of anti-FN antibody
FN15. Panel (a) shows left thymus from 8.2 week fetus no. 58. Panel (b) shows right thymus from 8.2 week fetal thymus no. 58 Panel (c)
shows post-natal thymus no. 112. Panels (a) and (b) show that anti-FN antibody reacted with thymic capsule, vessels and fibrous tissue at
the time of colonization with stem cells; anti-FN antibody also reacted with thymic vessels and HB in post-natal thymus (panel c). Panels (d)-
(f) show that HABP conjugated with biotin did not react with fetal thymus (no 58) at 8.2 weeks of gestation (panel d) while it did react with
thymus in panel (e) (no. 57) from 16 weeks of gestation and with normal post-natal thymus (no. 112) in panel (f). HAPB-biotin reacted with
thymic fibroblasts in the thymic capsule and with vessels (All panels X400.)
with retinoic acid (RA), which has been shown to induce
differentiation in a variety of epithelial cell types (32,33). RA
(1 u.M for 96 h), associated with the withdrawal of standard
TE media growth factors (epidermal growth factor and insulin),
induced differentiation in 29±5% (N = 3) of cells as deter-
mined by morphological change (Fig. 7) and reactivity with
mAb TE19 or STE1. In RA-treated cultures, 20±7% of TE
cells were reactive with mAb 11.24. As before, reactivity of
mAb 11.24 was highest on large TE cells as determined by
analysis of fluorescence versus forward scatter. These data
provide additional confirmation of the notion that CD44v9
expression on human TE cells was induced upon terminal
differentiation.
Detection of CD44 TE and thymocyte proteins by immuno-
blot analysis
To further analyze the isoforms of CD44 expressed by thymo-
cytes and TE cells, soluble extracts of cell surface proteins
from freshly isolated thymocytes, undifferentiated TE cells
and well-differentiated TE cells were separated by polyacryl-
amide gel electrophoresis, immobilized on nitrocellulose
membranes and CD44 proteins detected by immunoblot
analysis using indirect immunoperoxidase staining. As shown
in Fig.8(B), mAb A3D8 (to all forms of CD44) detected
predominantly 85 kDa proteins in both thymocytes and TE
cells from cultures that were not well differentiated. Also
detected in undifferentiated TE cells, albeit at a low level,
were at least four (-115, 150, 180 and >220 kDa) high
molecular weight isoforms of CD44 (Fig. 8C). All four of these
high molecular weight isoforms of CD44 reacted with mAb to
CD44v9 (not shown). While poorly differentiated TE cells
expressed high levels of the 85 kDa CD44S isoform of CD44,
well differentiated TE cells (from the culture shown in Fig. 4B)
expressed lower amounts of the 85 kDa form of CD44
(Fig. 8D). Expression of the 150, 180 and >220kDa high
molecular weight variant isoforms of CD44 increased with
differentiation while expression of the 115 kDa variant isoform
decreased (Fig. 8D).
Ontogeny of CD44 ligands HA and FN during human fetal
thymic development
Finally, to begin to understand the relevance of location and
timing of expression of CD44 isoforms in human thymus, we
studied the ontogeny of expression of two CD44 ligands, HA
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(34-37) and FN (38), in fetal thymus. At the time of first entry
of hematopoietic stem cells into the human thymic epithelial
rudiment, the thymic capsule vessels and scattered thymic
stromal cells expressed FN (Fig. 9a and b). In 13 (no. 56)
and 16 (no. 57) week fetal thymuses, anti-FN mAb FN15
reacted with fibrous septae and vessels (not shown). In post-
natal thymus containing HB, fibrous septae, vessels and HB
expressed FN (Fig. 9c). In contrast, in the recently colonized
8.2 week (no. 58) thymus and in the 13 week thymus, no
thymic HA was detected (Fig. 9d), although HABP-biotin
bound well to 8.2 week skin (not shown). However, at 16
weeks (no. 57) (Fig. 9e) and post-natally (no. 112) (Fig. 9f),
HABP-biotin bound well to thymic capsule, interlobular septae
and to vessels in 16 week thymus (no. 57) (Fig. 9e) and also,
to HB of post-natal thymus (no. 112) (Fig. 9f), in a distribution
similar to FN. Thus, FN was expressed throughout thymic
ontogeny beginning at 8.2 weeks, while thymic HA expression
was acquired around 16 weeks of gestational age.
Discussion
In this study, we have found that CD44 mAbs against all
CD44 isoforms reacted with thymic fibroblasts, thymocytes
and TE cells from the time of first colonization of the thymus
by stem cells, whereas mAbs against CD44 isoforms con-
taining v4, v6 or v9 inserts reacted only with terminally
differentiated TE cells in HB beginning at 16-19 weeks of
gestation Using mAb 11.24 against CD44v9, biochemical
studies and flow cytometry in vitro on undifferentiated and
differentiated TE cells confirmed the acquisition of CD44v9
expression with TE cell terminal differentiation. Finally, we
found that expression of two CD44 ligands, HA and FN,
differed in gestational age of expression, with FN present at
the time of thymic colonization, while HA expression was
acquired at 16 weeks.
The pattern of expression of CD44 isoforms and CD44
ligands in thymus was, in part, surprising. While nearly all
PBL could be induced upon activation by phorbol esters to
express variant isoforms of CD44 (15,16), the majority of
thymocytes could not. This observation is consistent with the
notion that thymocytes are not yet fully functional and require
additional maturation events either in the thymus prior to
emigration from the thymus or in the periphery after emigration
from the thymus (reviewed in 39). Since fibroblasts in most
tissues do not express variant isoforms of CD44 (16; D. D.
Patel etal., unpublished observations), it is not surprising that
thymic fibroblasts do not express CD44v detectable by mAbs.
While most epithelial cells express both CD44S and CD44v
isoforms (16,40), undifferentiated TE cells express predomi-
nantly CD44S and differentiated TE cells express predomi-
nantly CD44v. Thus, induction of CD44v expression is a marker
of terminally differentiating (squamous-shaped) medullary TE
cells in and around thymic HB.
The up-regulation of CD44v9, v4 and v10 expression with
TE cell differentiation and down-regulation of CD44S suggests
that the expression of CD44 isoforms is developmentally
regulated in TE cells. This change in the pattern of CD44
isoform expression during TE differentiation may be due to a
variety of processes including alternative promoter use, post-
transcriptional processing, message stability and post-trans-
lational modification. The most likely event is a change in the
mRNA splicing machinery, either by the acquisition of a pro-
splicing factor or the loss of an inhibitor, such that inclusion
of variant exons is favored over exclusion. For example,
differentiation has been shown to induce alternative splicing
of the 4.1 membrane skeletal RNA in erythroid cells (41), the
microtubule-associated tau gene RNA in neuroblastoma cells
(42) and FN RNA during chondrogenesis (43). To fully evaluate
this possibility, future studies examining the stability of CD44
mRNAs and proteins and the splicing patterns of CD44 RNAs
will be of interest.
CD44 has been implicated in the homing of bone marrow-
derived precursor T cells to the murine thymus. Not only is
CD44 expressed on murine pro-thymocytes capable of hom-
ing to and re-populating the thymus (44), antibodies to CD44
inhibited the homing of pro-thymocytes in vivo to the murine
thymus (45,46), although this may have been due to antibody
coated cells that were removed from the circulation by
phagocytosis in the liver (1) In humans, CD44 isoforms are
also expressed on thymic precursors (47) and antibodies to
CD44 inhibited the binding of lymphocytes to high endothelial
venules in lymph nodes (48,49).
HA is a glycosaminoglycan polymer with a molecular weight
of up to several million daltons that is a ligand for CD44 (34-
37). While a variety of lymphoid cells can be induced to bind
HA in vitro (reviewed in 1), the existence of a true physiologic
role for CD44-HA interactions in T cell development is contro-
versial Our data that HA is not expressed at the time of initial
colonization of the human thymus with thymocyte precursors
(8.2 weeks of fetal gestation) suggests that CD44-HA inter-
actions are not necessary for the migration of early thymic
precursors to or within the thymus. Since HA is detected
on thymic septae and vessels at later stages of thymic
development when the first wave of thymocytes has had time
to mature, it is possible that CD44-HA interactions may play
a role in thymocyte emigration from thymus. Furthermore, as
HA is expressed on fibrous septae, CD44-HA interactions
may serve to anchor stromal cells to the thymic extracellular
matrix (ECM). Transfection of a CD44" B cell line with CD44S
but not with CD44v8-10 conferred the ability to bind to lymph
node HEV in an HA-dependent manner (37). In addition,
Jurkat T cells transfected with CD44S but not those transfected
with CD44v8-10 could be induced by phorbol myristate
acetate treatment to bind HA (19), indicating that in the phorbol
myristate acetate-induced state CD44S, but not CD44v8-10,
can bind HA. However, we have demonstrated induction of
CD44v8-10 HA binding by mAb ligation of CD44v8-10 (19).
We and others have noted that the pattern of CD44v expres-
sion differs between simple and stratified epithelia, in that
high levels of CD44v4 and CD44v6 are expressed on stratified
but not on simple epithelia (16,40). Further, this pattern of
expression is that expected of a molecule of stratified epithelia
that mediates intracellular and cell-ECM but not cell-base-
ment membrane interactions (40). This pattern is similar to
another developmentally regulated ECM binding cell surface
proteoglycan, syndecan, that has two forms that vary between
simple and stratified epithelia (50,51).
A second ligand for CD44, FN (38), may be important
for both pro-thymocyte homing to thymus and for T cell
differentiation. FN consists of a family of very large (-500 kDa)
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glycoproteins that have clearly been shown in mice to mediate
the binding of immature thymocytes to thymic stromal cells
and to mediate thymocyte differentiation (52). Although these
effects were mediated primarily by the RGD sequence that
binds to integrins VLA-3 (CD49c/CD29), VLA-4 (CD49d/CD29)
and VLA-5 (CD49e/CD29) (52,53), CD44-FN interactions may
also play a role in these events. The chondroitin sulfated form
of purified lymphocyte CD44 binds the C-terminal heparin
binding domain of FN (38). However, it has been difficult to
isolate CD44-FN interactions in cell binding assays (1,38),
likely because of the predominance of integrin-FN inter-
actions. Our data that FN is expressed on thymic vessels
from the time of initial colonization of the thymus with pro-
thymocytes whereas HA is not detectable at this gestational
age suggests that FN-FN receptor (CD44 or VLAs) inter-
actions rather than CD44-HA interactions may be important
for early thymic development.
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